Kyowa Hakko Kirin completes biopharmaceutical API facility at Takasaki

Will contain one of the largest recombinant animal cell bioreactors in Japan

External view of the HA4 plant at Takasaki, Japan

Japanese pharmaceutical company Kyowa Hakko Kirin has completed construction of a GMP biopharmaceutical API manufacturing facility at its Takasaki plant in an investment of approximately JPY6bn (€43m; US$59m).

The 3,892m2 four-storey HA4 facility contains one of the largest bioreactors for recombinant animal cells (12,000L) in Japan, as well as a purification facility with a large column.

The company says the new bioreactor will enable it to offer large scale and stable manufacturing of high-quality pharmaceutical ingredients.

Operations will commence at the new facility in the first half of 2016.